Envoy Medical, Inc. 8-K

What Happened
Envoy Medical, Inc. (COCH) filed an 8-K on Feb 11, 2026 disclosing that its Compensation Committee approved stock option awards on Feb 5, 2026. CEO Brent Lucas was granted options to buy 200,000 shares of Class A Common Stock and Interim CFO Robert Potashnick was granted options to buy 15,000 shares, under the company’s 2023 Equity Incentive Plan.

Key Details

• Award Date: February 5, 2026; Form 8-K filed February 11, 2026.
• Total options granted: 215,000 shares (200,000 to CEO, 15,000 to Interim CFO).
• Exercise price: $0.53 per share (closing price on Nasdaq on Feb 5, 2026).
• Vesting: 25% after one year, remainder vests pro rata over the next 36 months.
• Term: Options expire 10 years after the Award Date (expires Feb 5, 2036).
• Awards issued under the Company’s 2023 Equity Incentive Plan on previously filed option forms.

Why It Matters
These grants align senior management compensation with shareholder value by tying pay to future stock performance. The awards create potential dilution if exercised (215,000 shares outstanding if all options are exercised) and will be recorded as equity-based compensation expense under accounting rules. Investors should note the exercise price equals the market price at grant ($0.53), standard vesting that encourages retention, and the 10-year term for potential future dilution.